Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
评估将抗CD38单克隆抗体纳入复发/难治性多发性骨髓瘤患者的二线或三线系统治疗的益处：来自法国真实世界EMMY研究的结果
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2025.287954
Chalopin, Thomas; Hulin, Cyrille; Royer, Bruno; Bastie, Jean-Noel; Bobin, Arthur; Merzoug, Karim Belhadj; Macro, Margaret; Karlin, Lionel; Jacquet, Caroline; Mohty, Mohamad; Frenzel, Laurent; Sonntag, Cécile; Fontan, Jean; Rigaudeau, Sophie; Roussel, Murielle; Sanhes, Laurence; Chaoui, Driss; Vincent, Laure; Orfeuvre, Hubert; Bouketouche, Malek; Garlantezec, Ronan; Decaux, Olivier; Perrot, Aurore
